Mycophenolate Mofetil for Injection 0.5g – For Research Use Only

Description

Mycophenolate mofetil (MMF) is the ester prodrug of mycophenolic acid (MPA), a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), essential for de novo guanosine nucleotide synthesis in lymphocytes. By depleting guanosine pools, MMF suppresses both T- and B-lymphocyte proliferation and promotes regulatory T?cell induction. It is clinically used to prevent graft rejection and treat autoimmune diseases. In research settings, the injectable form enables precise dosing in pre?transplant models, acute rejection simulations, pharmacokinetic studies, and investigation of JAK/STAT and NF??B pathway suppression. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

MMF is hydrolyzed into mycophenolic acid, which selectively inhibits IMPDH—critical for guanine nucleotide synthesis in lymphocytes. This suppresses lymphocyte proliferation and induces replication stress in activated T and B cells, while promoting regulatory T-cell expansion. MMF shows potent anti-inflammatory effects in lung injury and organ rejection models, making it ideal for use in preclinical transplant immunology, autoimmunity studies, and inflammatory pathway investigations.

Side Effects (For Reference Only in Research Models)

Clinical analogs demonstrate myelosuppression (leukopenia, anemia), gastrointestinal symptoms (nausea, diarrhea), infection risks including viral reactivation (CMV, BK virus), and increased risk of malignancy. It is embryotoxic and contraindicated in pregnancy. Thrombophlebitis may occur with rapid IV infusion. These findings inform safe dosing and monitoring in experimental protocols.

Disclaimer

Mycophenolate Mofetil for Injection is strictly intended for laboratory research use only. Not for human or veterinary therapeutic, diagnostic, or prophylactic use.